Thus, collectively, we propose that TTTTG-TRIB1 and TG-PCA3 are excellent genetic markers to prioritize for large-scale case-control studies as they are (i) consistently differentially expressed in prostate tumors compared to adjacent non-cancer cells, (ii) polymorphic, and (iii) are within genes regulated by (anti)-androgens (Table 1). This evidence concerns the gene TRIB1 and prostate neoplasm.